Wall Street Unplugged
Episode: 499March 16, 2017

Panna Sharma: Changing the Face of Cancer

Panna Sharma

Welcome back to another episode of Wall Street Unplugged!

On today’s show, I introduce listeners to Panna Sharma. Panna is the CEO and President of a small-cap, clinical and diagnostics company – Cancer Genetics (CGIX).

Panna brings together everything you need to know about the company. It’s core focus? Precision medicine. And the drug industry is betting big on it…

To start off the interview, Panna and I talk about how treatments and innovations in the industry are rapidly changing…

In the past, companies were betting on single drugs and routine treatments to cure all. But considering the complex, biological diversity of something like cancer, there has never been and never will be “one answer.”

Panna explains how the industry and his company in particular are making huge strides in the right direction.

Recently, we’ve seen a transfer from trial-and-error medicines to evidence-based medicine. And instead of dividing patients into groups based on thousands of outcomes, today you can now treat patients baseds on the details of their own unique genes.

The trend is the death of “one size fits all.”

And companies like Cancer Genetics are sitting at the center of it.

Panna Sharma

The business model, as Panna says, comes from a “multi-tiered” approach. The company focuses on drug design, clinical trials, and diagnosis development.

It’s a strategy leveraged from genomic data, innovation, and collaboration. And it benefits both side’s of the equation – the world of biotech/pharma development, as well as the patients.

Now for those that are familiar with my podcast, you know that I’m picky…

And you probably have heard about my show’s golden rule — To never bring on a CEO of a company I don’t personally believe in.

In other words, don’t take this as a sales pitch.

This company, no doubt, has long-term growth potential. And Panna has all the right answers to back it up…

After looking at what’s actually on paper, it was difficult to turn away. For one, there’s high insider ownership. But more important, Cancer Genetics is working with 8 out of the top 10 biotech companies.

A small company with strong partnerships with some of the biggest names in the industry is huge. This commercial traction alone is their strongest catalyst going forward.

The current share price is sitting just above $2.00. And valuations are at a steep discount compared to other traditional genomic diagnosis companies.

But before taking any action, note that earnings are only one week away. And considering the current shape of the industry, be sure to do some homework. Again, this is a long-term play… And resources like this interview are a great place to start.

Not only is this a company that should be on everyone’s radar, this is one of those “feel good” stories. And I’m more than happy to introduce listeners to the opportunity.

Links & Resources

Stocks Mentioned

  • Skyharbour Resources (SYH.V)
  • Frist Majestic Silver Corp (AG)
  • Gold Standard Ventures Corp (GSV)
  • Cancer Genetics, Inc. (CGIX)
  • Pfizer Inc. (PFE)
  • Merck & Co., Inc. (MRK)
  • Gilead Sciences, Inc. (GILD)
  • GlaxoSmithKline plc (GSK)

What’s really moving these markets?
Get free daily updates
More Wall Street Unplugged

Is GameStop a buy?

A look at the latest CPI data… Are interest rate cuts priced in? … Is Apple a buy? … Why the AI race should scare you… GameStop proves the market is rigged… And why Trump should pardon Hunter Biden.

Elon Musk

Is Elon Musk about to dominate the AI landscape?

2 market indicators are telling opposite stories—which one is true? … Musk's new AI startup… Why Zuckerberg is getting major AI street cred… How to profit from AI… This crypto lawyer should be shot… And why you need crypto exposure.


Will Biden veto the crypto bill?

Are Target and Autozone buys on their pullbacks? … Don't be fooled by Lowe's earnings beat… Avoid this dangerous cybersecurity stock… And will Biden follow through on his crypto bill veto?

Meme stocks are back! [My picks]

Don't trust the headlines about the CPI… Biden is a hypocrite about tariffs… Dimon's imminent warning… Don't believe these lies about gold… Bitcoin's next bull market? … Meme stocks are back… And these highly shorted stocks are poised to skyrocket.

This popular uranium stock will go to $0

The uranium bull market is just beginning… How AI is driving uranium demand… One popular uranium stock to avoid… And two investments to play uranium's upside. Plus, a stock to buy instead of Disney… And this "AI" favorite is faltering.